International Journal of Cancer Management

Published by: Kowsar

Designing a Chimeric Vaccine Against Colorectal Cancer

Ziba Veisi Malekshahi 1 , Masoumeh Rajabibazl 2 , 3 , Walead Ebrahimizadeh 4 , Jafar Amani 5 , * and Babak Negahdari 1 , **
Authors Information
1 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical sciences, Tehran, IR Iran
4 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
5 Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Corresponding Authors:
Article information
  • International Journal of Cancer Management: December 2017, 10 (12); e7743
  • Published Online: December 29, 2017
  • Article Type: Research Article
  • Received: October 22, 2016
  • Revised: December 10, 2016
  • Accepted: December 12, 2017
  • DOI: 10.5812/ijcm.7743

To Cite: Veisi Malekshahi Z, Rajabibazl M, Ebrahimizadeh W, Amani J, Negahdari B. Designing a Chimeric Vaccine Against Colorectal Cancer, Int J Cancer Manag. 2017 ; 10(12):e7743. doi: 10.5812/ijcm.7743.

Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Safaee A, Fatemi SR, Ashtari S, Vahedi M, Moghimi-Dehkordi B, Zali MR. Four years incidence rate of colorectal cancer in Iran: a survey of national cancer registry data - implications for screening. Asian Pac J Cancer Prev. 2012;13(6):2695-8. [PubMed: 22938443].
  • 2. Ohkado A, Yanabu N, Kimura F, Kamimura K, Sumiyoshi T, Wakuya J, et al. [A case of mesothelioma of the pleura with pneumothorax]. Kyobu Geka. 1989;42(7):565-8. [PubMed: 2796096].
  • 3. Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2010;24(4):417-25. doi: 10.1016/j.bpg.2010.06.005. [PubMed: 20833346].
  • 4. Irvin G3, Horsley J3, Caruana JJ. The morbidity and mortality of emergent operations for colorectal disease. Ann Surg. 1984;199(5):598-603. [PubMed: 6609686].
  • 5. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis. 2008;23(7):683-8. doi: 10.1007/s00384-008-0463-7. [PubMed: 18330578].
  • 6. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol. 2010;2010:174378. doi: 10.1155/2010/174378. [PubMed: 20368780].
  • 7. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3(8):630-41. doi: 10.1038/nri1150. [PubMed: 12974478].
  • 8. Mellgren SI, Johnsen HJ. [Steroid-induced myopathy. Clinical and muscle pathologic aspects with a case report]. Tidsskr Nor Laegeforen. 1979;99(3):163-4. [PubMed: 419494].
  • 9. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348-60. doi: 10.1016/j.ejca.2007.03.021. [PubMed: 17512720].
  • 10. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Strigard K, Eriksson E, Samanci A, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res. 2004;10(10):3273-81. doi: 10.1158/1078-0432.CCR-03-0706. [PubMed: 15161680].
  • 11. Dahlquist G, Sterky G, Ivarsson JI, Tengvald K, Wall S. Health problems and care in young families--load of illness and patterns of illness behaviour. Scand J Prim Health Care. 1987;5(2):79-86. [PubMed: 3616277].
  • 12. Paterson Y, Singh R. Administering a Listeria vaccine with a strain expressing an antigen fused to a truncated LLO protein; cancer vaccines; anticarcinogenic agents. Google Patents; 2010.
  • 13. Bos R, van Duikeren S, van Hall T, Lauwen MM, Parrington M, Berinstein NL, et al. Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol. 2007;179(9):6115-22. [PubMed: 17947686].
  • 14. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67-81. doi: 10.1006/scbi.1998.0119. [PubMed: 10202129].
  • 15. Misener S, Krawetz SA. Bioinformatics methods and protocols. 132. Springer Science & Business Media; 1999.
  • 16. Gish W, States DJ. Identification of protein coding regions by database similarity search. Nat Genet. 1993;3(3):266-72. doi: 10.1038/ng0393-266. [PubMed: 8485583].
  • 17. Casado V, Lluis C, Canela E, Franco R, Mallol J. The distribution of A1 adenosine receptor and 5'-nucleotidase in pig brain cortex subcellular fractions. Neurochem Res. 1992;17(2):129-39. [PubMed: 1538830].
  • 18. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007;8:4. doi: 10.1186/1471-2105-8-4. [PubMed: 17207271].
  • 19. Sen TZ, Jernigan RL, Garnier J, Kloczkowski A. GOR V server for protein secondary structure prediction. Bioinformatics. 2005;21(11):2787-8. doi: 10.1093/bioinformatics/bti408. [PubMed: 15797907].
  • 20. Lissoni P, Galli MA, Barni S, Colombo V, Pelizzoni F, Fumagalli R, et al. [The cardiovascular toxicity of interleukin-2: the pathogenic mechanisms and treatment]. G Ital Cardiol. 1990;20(7):631-5. [PubMed: 2245901].
  • 21. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc. 2009;4(3):363-71. doi: 10.1038/nprot.2009.2. [PubMed: 19247286].
  • 22. Lovell SC, Davis IW, Arendall W3, de Bakker PI, Word JM, Prisant MG, et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins. 2003;50(3):437-50. doi: 10.1002/prot.10286. [PubMed: 12557186].
  • 23. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server issue):W407-10. doi: 10.1093/nar/gkm290. [PubMed: 17517781].
  • 24. Chambers JE, Yarbrough JD. Parathion and methyl parathion toxicity to insecticide-resistant and susceptible mosquitofish (Gambusia affinis). Bull Environ Contam Toxicol. 1974;11(4):315-20. [PubMed: 4433817].
  • 25. Flickinger KS, Culp LA. Dermal fibroblasts from Down's syndrome patients share a cycloheximide-induced deficiency in collagen adhesion responses with normal aging cells. Exp Cell Res. 1990;189(2):189-201. [PubMed: 2142462].
  • 26. Tochilin VI. [Nodular goiter and cancer of the thyroid]. Vestn Khir Im I I Grek. 1989;143(11):18-20. [PubMed: 2633425].
  • 27. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31(13):3406-15. [PubMed: 12824337].
  • 28. Graf M, Deml L, Wagner R. Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Mol Diagnos Infect Dis. 2004:197-210.
  • 29. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. Springer; 2005.
  • 30. Smialowski P, Martin-Galiano AJ, Mikolajka A, Girschick T, Holak TA, Frishman D. Protein solubility: sequence based prediction and experimental verification. Bioinformatics. 2007;23(19):2536-42. doi: 10.1093/bioinformatics/btl623. [PubMed: 17150993].
  • 31. Magnan CN, Randall A, Baldi P. SOLpro: accurate sequence-based prediction of protein solubility. Bioinformatics. 2009;25(17):2200-7. doi: 10.1093/bioinformatics/btp386. [PubMed: 19549632].
  • 32. Cserzo M, Wallin E, Simon I, von Heijne G, Elofsson A. Prediction of transmembrane alpha-helices in prokaryotic membrane proteins: the dense alignment surface method. Protein Eng. 1997;10(6):673-6. [PubMed: 9278280].
  • 33. Heringa J, Frishman D, Argos P. Chapter 4 Computational methods relating protein sequence and structure. 1997.
  • 34. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res. 2010;38(Web Server issue):W529-33. doi: 10.1093/nar/gkq399. [PubMed: 20478830].
  • 35. Yu CS, Chen YC, Lu CH, Hwang JK. Prediction of protein subcellular localization. Proteins. 2006;64(3):643-51. doi: 10.1002/prot.21018. [PubMed: 16752418].
  • 36. Viklund H, Elofsson A. OCTOPUS: improving topology prediction by two-track ANN-based preference scores and an extended topological grammar. Bioinformatics. 2008;24(15):1662-8. doi: 10.1093/bioinformatics/btn221. [PubMed: 18474507].
  • 37. Nielsen H, Engelbrecht J, Brunak S, von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng. 1997;10(1):1-6. [PubMed: 9051728].
  • 38. El-Manzalawy Y, Dobbs D, Honavar V. Predicting linear B-cell epitopes using string kernels. J Mol Recognit. 2008;21(4):243-55. doi: 10.1002/jmr.893. [PubMed: 18496882].
  • 39. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006;65(1):40-8. doi: 10.1002/prot.21078. [PubMed: 16894596].
  • 40. Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2:2. doi: 10.1186/1745-7580-2-2. [PubMed: 16635264].
  • 41. Sun J, Wu D, Xu T, Wang X, Xu X, Tao L, et al. SEPPA: a computational server for spatial epitope prediction of protein antigens. Nucleic Acids Res. 2009;37(Web Server issue):W612-6. doi: 10.1093/nar/gkp417. [PubMed: 19465377].
  • 42. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008;9:514. doi: 10.1186/1471-2105-9-514. [PubMed: 19055730].
  • 43. Kesmir C, Nussbaum AK, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng. 2002;15(4):287-96. [PubMed: 11983929].
  • 44. Holzhutter HG, Kloetzel PM. A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys J. 2000;79(3):1196-205. doi: 10.1016/S0006-3495(00)76374-0. [PubMed: 10968984].
  • 45. Diez-Rivero CM, Lafuente EM, Reche PA. Computational analysis and modeling of cleavage by the immunoproteasome and the constitutive proteasome. BMC Bioinformatics. 2010;11:479. doi: 10.1186/1471-2105-11-479. [PubMed: 20863374].
  • 46. Bhasin M, Raghava GP. Analysis and prediction of affinity of TAP binding peptides using cascade SVM. Protein Sci. 2004;13(3):596-607. doi: 10.1110/ps.03373104. [PubMed: 14978300].
  • 47. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 2007;8:424. doi: 10.1186/1471-2105-8-424. [PubMed: 17973982].
  • 48. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-9. [PubMed: 10602881].
  • 49. Bhasin M, Raghava GP. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004;22(23-24):3195-204. doi: 10.1016/j.vaccine.2004.02.005. [PubMed: 15297074].
  • 50. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics. 2008;24(11):1397-8. doi: 10.1093/bioinformatics/btn128. [PubMed: 18413329].
  • 51. Singh H, Raghava GP. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics. 2003;19(8):1009-14. [PubMed: 12761064].
  • 52. Adams HP, Koziol JA. Prediction of binding to MHC class I molecules. J Immunol Methods. 1995;185(2):181-90. [PubMed: 7561128].
  • 53. Lata S, Bhasin M, Raghava GP. Application of machine learning techniques in predicting MHC binders. Methods Mol Biol. 2007;409:201-15. doi: 10.1007/978-1-60327-118-9_14. [PubMed: 18450002].
  • 54. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics. 2001;17(12):1236-7. [PubMed: 11751237].
  • 55. Johansen MB, Kiemer L, Brunak S. Analysis and prediction of mammalian protein glycation. Glycobiology. 2006;16(9):844-53. doi: 10.1093/glycob/cwl009. [PubMed: 16762979].
  • 56. Gupta R, Jung E, Brunak S. Prediction of N-glycosylation sites in human proteins. 2016.
  • 57. Gupta R, Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Pac Symp Biocomput. 2002:310-22. [PubMed: 11928486].
  • 58. Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. 2013;32(10):1478-88. doi: 10.1038/emboj.2013.79. [PubMed: 23584533].
  • 59. Bologna G, Yvon C, Duvaud S, Veuthey AL. N-Terminal myristoylation predictions by ensembles of neural networks. Proteomics. 2004;4(6):1626-32. doi: 10.1002/pmic.200300783. [PubMed: 15174132].
  • 60. Eisenhaber B, Bork P, Eisenhaber F. Sequence properties of GPI-anchored proteins near the omega-site: constraints for the polypeptide binding site of the putative transamidase. Protein Eng. 1998;11(12):1155-61. [PubMed: 9930665].
  • 61. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191-7. doi: 10.1055/s-0029-1242458. [PubMed: 21037809].
  • 62. Vigneron N. Human Tumor Antigens and Cancer Immunotherapy. Biomed Res Int. 2015;2015:948501. doi: 10.1155/2015/948501. [PubMed: 26161423].
  • 63. Dzivenu OK, O’Donnell-Tormey J, O’Donnell-Tormey J. Cancer and the immune system: the vital connection. Cancer Research Institute; 2003.
  • 64. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-77. doi: 10.1038/nrc3258. [PubMed: 22437871].
  • 65. Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med. 2011;1(1). a007252. doi: 10.1101/cshperspect.a007252. [PubMed: 22229122].
  • 66. Dermime S, Armstrong A, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br Med Bull. 2002;62:149-62. [PubMed: 12176857].
  • 67. Somers VA, Brandwijk RJ, Joosten B, Moerkerk PT, Arends JW, Menheere P, et al. A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J Immunol. 2002;169(5):2772-80. [PubMed: 12193752].
  • 68. Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M, et al. Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology. 2003;64(4):443-9. doi: 10.1159/000070305. [PubMed: 12759544].
  • 69. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68(6):1075-82. [PubMed: 14524394].
  • 70. Turriziani M, Fantini M, Benvenuto M, Izzi V, Masuelli L, Sacchetti P, et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov. 2012;7(3):265-96. [PubMed: 22630596].
  • 71. Ananenko AA, Malinovskaia VV, Pertseva NG, Bezrukov K, Sultanov AT. [State of lipid peroxidation system and antioxidant defense in acute respiratory viral infection in children and the principles of pathogenetic therapy]. Pediatriia. 1989;(1):27-30. [PubMed: 2710600].
  • 72. Park IJ, Choi GS, Jun SH. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res. 2009;29(10):4303-8. [PubMed: 19846991].
  • 73. Ribas A, Butterfield LH, Economou JS. Genetic immunotherapy for cancer. Oncologist. 2000;5(2):87-98. [PubMed: 10794799].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments